Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Environmental tobacco smoke and peripheral arterial disease: a review

Ngu NL, McEvoy M

(2017), Atherosclerosis, 266, 113-20

DOI: 10.1016/j.atherosclerosis.2017.09.024

Investigation of IRGANOX® 1076 as a dosimeter for clinical X-ray, electron and proton beams and its EPR angular response

Smith C, Ankers E, Best S, Gagliardi F, Katahira K, Tsunei Y, Takahiro T, Geso M

(2017), Rad Phys Chem, 141, 284-91

DOI: 10.1016/j.radphyschem.2017.08.002

Real-time in-vivo dosimetry

Beaulieu L, Franich RD, Smith RL

(2017), In: Song WY, Tanderup K, Pieters B (eds), Emerging Technologies in Brachytherapy, CRC Press, Chapter 9,

Stereotactic ablative body radiotherapy for the treatment of spinal oligometastases

Chang JH, Gandhidasan S, Finnigan R, Whalley D, Nair R, Herschtal A, Eade T, Kneebone A, Ruben J, Foote M, Siva S

(2017), Clin Oncol, 29(7), e119-e25

DOI: 10.1016/j.clon.2017.02.004

Long-term survivors of glioblastoma: a closer look

Gately L, McLachlan S, Philip J, Ruben J, Dowling A

(2017), J Neurooncol, 136(1), 155-62

DOI: 10.1007/s11060-017-2635-1

The effects of gold nanoparticles concentrations and beam quality/LET on dose enhancement when irradiated with X-rays and protons using alanine/EPR dosimetry

Smith CL, Best SP, Gagliardi F, Tominaga T, Geso M

(2017), Radiat Meas, 106, 352-6

DOI: 10.1016/j.radmeas.2017.01.019

A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate 192 Ir brachytherapy

Ma Y, Vijande J, Ballester F, Tedgren ?C, Granero D, Haworth A, Mourtada F, Fonseca GP, Zourari K, Papagiannis P, Rivard MJ, Siebert FA, Sloboda RS, Smith R, Chamberland MJP, Thomson RM, Verhaegen F, Beaulieu L

(2017), Med Phys, 44(11), 5961-76

DOI: 10.1002/mp.12459

A randomized controlled trial of an additional funding intervention to improve clinical trial enrollment

Parker C, Snyder R, Jefford M, Dilts D, Wolfe R, Millar J

(2017), J Natl Compr Canc Netw, 15(9), 1104-10

DOI: 10.6004/jnccn.2017.0150

Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer

Ong WL, Foroudi F, Evans S, Millar JL

(2017), BJU Int, 120(Suppl 3), 35-42

DOI: 10.1111/bju.13969

3D catheter reconstruction in HDR prostate brachytherapy for pre-treatment verification using a flat panel detector

Smith RL, Haworth A, Panettieri V, Millar JL, Franich RD

(2017), Phys Med, 39, 121-31

DOI: 10.1016/j.ejmp.2017.06.008

Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes

Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS

(2017), BMJ Open, 7(11), e017006

DOI: 10.1136/bmjopen-2017-017006

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer

Woodford K, Panettieri V, Tran Le T, Senthi S

(2017), Clin Trans Radiat Oncol, 6, 21-4

DOI: 10.1016/j.ctro.2017.08.001

Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial

Owen PJ, Daly RM, Livingston PM, Mundell NL, Via JD, Millar JL, Fraser SF

(2017), Trials, 18, 451

DOI: 10.1186/s13063-017-2185-z

Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia

Kirkman M, Young K, Evans S, Millar JL, Fisher J, Mazza D, Ruseckaite R

(2017), BMC Cancer, 17, 704

DOI: 10.1186/s12885-017-3699-1

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Duschesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S

(2017), Lancet Oncol, 18(9), 1192-1201

DOI: 10.1016/S1470-2045(17)30426-6

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers

Oberoi D, White VM, Seymour JF, Miles Prince H, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J, Doo NW, Giles G

(2017), Support Care Cancer, 25(11), 3447-56

DOI: 10.1007/s00520-017-3766-9

Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study

Papa NP, MacInnis RJ, Jayasekara H, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG

(2017), Prostate Cancer Prostatic Dis, 20(3), 305-10

DOI: 10.1038/pcan.2017.12

Ejaculatory frequency and the risk of aggressive prostate cancer: findings from a case-control study

Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG

(2017), Urol Oncol, 35(8), 530e7-13

DOI: 10.1016/j.urolonc.2017.03.007

Population-based study of grade progression in patients who harboured Gleason 3 + 3

Sampurno F, Earnest A, Millar J, Frydenberg M, Murphy D, Delprado W, Evans S

(2017), World J Urol, 35(11), 1689-99

DOI: 10.1007/s00345-017-2047-z

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study

White V, Marco DJT, Bolton D, Davis ID, Jefford M, Hill D, Prince HM, Millar JL, Winship IM, Coory M, Giles GG

(2017), BJU Int, 120(Suppl 3), 6-14

DOI: 10.1111/bju.13889

4 5 6 7 8